Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ACAB) is a clinical-stage biopharmaceutical company that reached the public markets via a SPAC transaction, operating in the biotechnology and life sciences sector with a focus on antibody engineering for oncology and other therapeutic areas. The company filed a Form 10-Q with the Securities and Exchange Commission on August 22, 2023, under accession number 0001193125-23-218080, reflecting its status as an active reporting issuer following completion of its de-SPAC transaction. Abpro's pipeline is centered on bispecific antibody candidates targeting cancer and inflammatory diseases. To access full sponsor details, deal timelines, filing histories, and real-time analytics on ACAB and every other SPAC in the market, sign up for SpacDesk at spacdesk.com.